Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2025
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Vincent Vultaggio [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On June 18, 2025, Vincent Vultaggio, the Company’s Senior Vice President, Finance and Principal Accounting Officer and interim principal financial officer , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of a to-be-determined number of shares of the Company’s common stock until February 26, 2027. The actual number of shares to be sold under the Rule 10b5-1 trading arrangement will equal 15% of shares received upon the occurrence of future restricted stock unit vesting events, net of any shares sold to cover tax obligations.
Name	Vincent Vultaggio
Title	Senior Vice President, Finance and Principal Accounting Officer and interim principal financial officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 18, 2025
Expiration Date	February 26, 2027
Arrangement Duration	618 days

Zentalis Pharmaceuticals, Inc. 10-Q